PILR-β Inhibitors
PILR-β inhibitors encompass a range of chemical compounds that indirectly mitigate the activity of this protein through various biochemical pathways. Erlotinib, by inhibiting EGFR, may alter the immune response in which PILR-β plays a part, potentially leading to decreased PILR-β activity as the inflammatory milieu is modulated. Similarly, Sorafenib and ZM336372, both acting as RAF kinase inhibitors, can affect the downstream signaling that influences immune cell activation and thus PILR-β activity. Imatinib and Dasatinib, by targeting tyrosine kinases such as BCR-ABL, c-KIT, and PDGFR, could suppress the macrophage activation and subsequent signaling cascades that involve PILR-β. The PI3Kδ-specific inhibitory action of Idelalisib and the broader PI3K pathway inhibition by LY294002 are likely to impact PILR-β function due to their roles in modulating immune cell activation and signaling.
Rapamycin, with its mTOR inhibitory effects, and Bortezomib, through proteasome inhibition, affect cell growth, proliferation, and survival, which are critical for the immune cells expressing PILR-β. The alteration in immune cell function resulting from these inhibitors could lead to a reduced activity of PILR-β, given its role in these cells. Venetoclax and Lenalidomide, targeting BCL-2 and immune modulation respectively, have the potential to decrease the survival of PILR-β expressing cells or modulate the immune response against which PILR-β operates, thereby diminishing its activity. Additionally, PD98059, a MEK inhibitor, disrupts the MAPK/ERK pathway integral for immune cell signaling, potentially impacting PILR-β function. These compounds, through their distinct but interconnected pathways, collectively contribute to the indirect inhibition of PILR-β, reflecting a multifaceted approach to modulating this protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that can downregulate signaling pathways which may indirectly influence PILR-β activity by altering the immune response, as EGFR signaling can impact the inflammatory response where PILR-β is involved. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor specifically targeting BCR-ABL, c-KIT, and PDGFR. While primarily used for certain cancers, its inhibition of PDGFR could reduce macrophage activation and thus potentially decrease PILR-β mediated immune responses. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor which also inhibits VEGFR and PDGFR. It's known to affect angiogenesis and could also impact immune cell interactions where PILR-β is expressed, altering its activity indirectly. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Idelalisib is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), an enzyme involved in immune cell activation. Inhibition of PI3Kδ may impact PILR-β function indirectly through altered immune cell signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-target tyrosine kinase inhibitor, with activity against BCR-ABL and SRC family kinases. It could affect PILR-β function indirectly through modulation of immune cell activation and signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that affects cell growth and proliferation. Since PILR-β is expressed on immune cells, rapamycin's inhibitory effect on T cells and other immune cell types could indirectly decrease PILR-β activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt multiple cell signaling pathways, including those in immune cells. By inhibiting NF-κB activation, it could indirectly reduce PILR-β activity by changing immune cell responses. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a selective BCL-2 inhibitor, leading to programmed cell death in certain cells. It could indirectly affect PILR-β function by reducing the survival of cells that express PILR-β. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide affects the immune system and has anti-inflammatory properties. It may indirectly affect PILR-β by modulating the immune responses in which PILR-β is implicated. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling pathways in immune cells. By changing the activation state of these cells, PILR-β's function could be indirectly altered. | ||||||